 | • レポートコード：MRC2303I0104 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界のデジタルパソロジー市場規模が、予測期間中に年平均11.7%で成長すると予測しています。本レポートは、デジタルパソロジーの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（スキャナー、ソフトウェア、ストレージシステム、その他）分析、用途別（病気診断、創薬、教育＆訓練）分析、エンドユーザー別（製薬/バイオテクノロジー企業/CRO、病院＆リファレンスラボラトリー、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、3DHistech Ltd、Hamamatsu Photonics K.K.、Koninklijke Philips NV、Danaher Corporation (Leica Biosystems Nussloch GmbH)、Mikroscan Technologies Inc、Nikon Corporation、Olympus Corporation、Proscia Inc.、F. Hoffmann-La Roche Ltd (Ventana Medical Systems Inc.)、Visiopharm A/S、Sectra AG、Leica Biosystems、XIFIN, Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のデジタルパソロジー市場規模：製品別 - スキャナーの市場規模 - ソフトウェアの市場規模 - ストレージシステムの市場規模 - その他製品の市場規模 ・世界のデジタルパソロジー市場規模：用途別 - 病気診断における市場規模 - 創薬における市場規模 - 教育＆訓練における市場規模 ・世界のデジタルパソロジー市場規模：エンドユーザー別 - 製薬/バイオテクノロジー企業/CROにおける市場規模 - 病院＆リファレンスラボラトリーにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界のデジタルパソロジー市場規模：地域別 - 北米のデジタルパソロジー市場規模 アメリカのデジタルパソロジー市場規模 カナダのデジタルパソロジー市場規模 メキシコのデジタルパソロジー市場規模 … - ヨーロッパのデジタルパソロジー市場規模 ドイツのデジタルパソロジー市場規模 イギリスのデジタルパソロジー市場規模 フランスのデジタルパソロジー市場規模 … - アジア太平洋のデジタルパソロジー市場規模 中国のデジタルパソロジー市場規模 日本のデジタルパソロジー市場規模 インドのデジタルパソロジー市場規模 … - 中東/南米のデジタルパソロジー市場規模 南アフリカのデジタルパソロジー市場規模 ブラジルのデジタルパソロジー市場規模 アルゼンチンのデジタルパソロジー市場規模 … - その他地域のデジタルパソロジー市場規模 ・競争状況 ・市場機会・将来の動向 |
The digital pathology market is expected to register a CAGR of 11.7% over the forecast period
During the COVID-19 pandemic, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms focused on effective and rapid technologies for the fast diagnosis of COVID-19 and to develop vaccines/new therapeutics to overcome the pandemic situation. The COVID-19 pandemic challenged diagnostic services when many histopathology departments already faced a diminishing workforce and increasing workload. Also, the COVID-19 pandemic in 2020, had a profound impact on routine pathology services. Digital pathology played a key role in safeguarding clinical services and pathology-based research during the pandemic 2020. For instance, according to an article published by BMJ Publishing Group Ltd & Association of Clinical Pathologists, in September 2021, there was a large jump in the number of pathologists employing home offices. And the number of primary diagnoses and consultations done via digital pathology significantly increased. Half of the respondents agreed that digital pathology (DP) had facilitated the maintenance of diagnostic practices. Moreover, the investment in laboratory expansion and market penetration of key manufacturers are likely to propel the market growth. For instance, according to the Department of Health and Human Services (HHS) report in 2022, during the pandemic (March 2020- February 2021), there were more than 28 million visits, which is way higher than prepandemic period. Thus, telehealth consultation is expected to boost the market growth.
The increasing number of teleconsultations, rising adoption of digital pathology to enhance lab efficiency, and increasing application in drug discovery and companion diagnostics are driving the digital pathology market. The use of digital pathology in disease diagnosis is also increasing, due to the integration of digital pathology with digital tools, barcoding, specimen tracking, and digital dictation. This also improves the safety, quality, and efficiency of disease diagnoses in pathology laboratories. For instance, according to an article published by WHO, in 2022, digital pathology is expected to have enormous potential to make routine pathology practice more efficient and accurate due to ease of use and the ability to work remotely. As per the report published by Deontics Ltd, in September 2022, artificial intelligence (AI)-based assistance systems are boosting image processing in the diagnostic sectors. These intelligent AI systems can employ a variety of algorithms, whether in radiology or pathology, to assist clinicians and specialists, in making quicker and safer judgments.
The market is also expected to be driven by the increasing adoption of telepathology, rising investment in healthcare in developed countries, market penetration of key manufacturers in the developing region, and an increasing focus on drug discovery. For instance, in April 2022, GlaxoSmithKline recruited PathAI to bring digital pathology Artificial intelligence to cancer, Non-alcoholic steatohepatitis (NASH) drug development. Aditionally, the 2022 EU4Health work program has been allocated a budget of more than EUR 835 million (USD 706.41 million) to boost health systems in Europe, including around EUR 77 million (USD 65.14 million) for digital investment. The creation of the European health data space, which intends to facilitate a greater exchange and access across member states to health data is likely to receive funds from the digital strand. Such government initiatives associated with the technological advancements in the healthcare IT field along with initiatives by the key player are likely to boost the growth of the market over the forecast period.
Therefore, the factors such as increasing number of teleconsultations, rising adoption of digital pathology to enhance lab efficiency, and increasing application in drug discovery and companion diagnostics are collectively driving the studied market growth over the forecast period. However, factors such as stringent regulatory concerns for primary diagnosis and lack of standard guidelines for digital pathology may impede market growth over the forecast period.
Digital Pathology Market Trends
Disease Diagnosis Segment is Expected to Hold Significant Share Over the Forecast Period
Digital diagnosis plays a prominent role in diagnosing various chronic diseases as it helps determine and understand the cause of diseases. Digital pathology is on the verge of becoming a mainstream option for routine diagnostics. The COVID-19 pandemic and the associated social distancing restrictions boosted the digital pathology market. In January 2022, to advance the COVID-19 diagnostic reporting tools and speed up public use of diagnostic tools, Health and Human Services (HHS) organized a hurried, two-month build cycle using the “TOPx Toolkit” developed by the U.S. Census Bureau with 15 industry-led teams. This made it simpler for people and organizations to report positive/negative test results safely.
Globally, there has been an increasing burden of chronic and infectious diseases such as cardiovascular, cancer, diabetes, influenza, orthopaedic and neurology disorders, leading to disability and negatively impacting people’s physical and mental well-being. According to the British Heart Foundation statistics published in January 2022, there were approximately 7.6 million people with heart disease in the United Kingdom due to cardiovascular disorders (CVDs). Due to the rising burden of cardiovascular diseases, there is an increasing demand for innovative technologies diagnosing cardiovascular diseases, thereby driving the market’s growth.
The integration of digital pathology with digital tools (barcoding, specimen tracking, and digital dictation) improvises the safety, quality, and efficiency of disease diagnosis in pathology laboratories. Digital pathology platform has a provision of instant sharing of whole slides to multiple pathologists, for providing their inputs in a case at a time. For instance, in January 2021, Roche reported CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making fast, accurate patient diagnoses of breast cancer. Hence, with the advantages of using digital pathology for disease diagnosis, the segment is expected to grow at a steady rate in the forecast period.
Hence, owing to the factors such as increasing burden of chronic and infectious diseases and integration of digital pathology, the disease diagnosis segment is estimated to witness significant growth over the forecast period.
North America is Expected to Dominate the Digital Pathology Market Over the Forecast Period
The primary driving factors for the growth of the North American digital pathology market are the growing burden of chronic diseases, rising adoption of technologies in chronic disease management, increasing investments, rising product launches, and initiatives taken by the key market players. The United States within North America is expected to grow significantly during the study period. The rising burden of chronic diseases such as cancer, Alzheimer’s disease, and others is expected to boost the digital diagnostics market. For instance, the American Cancer Society, 2022 estimated that about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer will be reported in 2022 from Kidney cancer. Furthermore, the International Diabetes Federation (IDF) published in December 2021, an estimated 14 million adults in Mexico were living with diabetes in 2021. Also, as per a press release by the government of Canada published in August 2021, diabetes is one of the major chronic diseases affecting Canadians where over 3 million Canadians or 8.8% of the population were diagnosed with diabetes and 6.1% of Canadian adults were at high risk of developing diabetes as of August 2021. The high burden of cancer is expected to boost the demand for digital pathology, thereby driving the market growth.
The launch of products and services in the region will also drive the market significantly. For instance, in March 2022, Digital Diagnostics and Baxter International Inc. announced a long-term strategic partnership to help front-line care providers deliver high-quality care and improve care outcomes by offering Digital Diagnostics’ IDx-DR autonomous AI software as a diagnostic service combined with the Welch Allyn RetinaVue 700 Imager. This combination can give providers a clear view of diagnostic information valuable for a treatment plan, thus driving the market.
Moreover, strategies such as rising partnerships, expansion, and increasing investments by major players in the market will also boost innovation in the region, thereby boosting the market in the region. For instance, in October 2021, Neuberg Diagnostics expanded its presence in the United States region by launching one of the first laboratory in the United States. The Neuberg Centre for Genomic Medicine (NCGM) ill focus on genomic and molecular testing based on next-generation sequencing (NGS) techniques through digital pathology systems.
Thus, owing to the factors such as growing burden of chronic diseases, rising adoption of technologies in chronic disease management, and initiatives taken by the key market players, is expected to drive market growth in North America region during the forecast period.
Digital Pathology Market Competitor Analysis
The digital pathology market is consolidated in nature due to the presence of few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold the market shares and are well known, including Nikon Corporation, Danaher Corporation (Leica Biosystems Nussloch GmbH), Hamamatsu Photonics KK, Mikroscan Technologies Inc., 3DHistech Ltd, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Number of Tele-consultations
4.2.2 Rising Adoption of Digital Pathology to Enhance Lab Efficiency
4.2.3 Increasing Application in Drug Discovery and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulatory Concerns for Primary Diagnosis
4.3.2 Lack of Standard Guidelines for Digital Pathology
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Product
5.1.1 Scanner
5.1.2 Software
5.1.3 Storage Systems
5.1.4 Other Products
5.2 By Application
5.2.1 Disease Diagnosis
5.2.2 Drug Discovery
5.2.3 Education and Training
5.3 By End User
5.3.1 Pharmaceutical, Biotechnology, Companies and CROs
5.3.2 Hospital and Reference Laboratories
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3DHistech Ltd
6.1.2 Hamamatsu Photonics K.K.
6.1.3 Koninklijke Philips NV
6.1.4 Danaher Corporation (Leica Biosystems Nussloch GmbH)
6.1.5 Mikroscan Technologies Inc
6.1.6 Nikon Corporation
6.1.7 Olympus Corporation
6.1.8 Proscia Inc.
6.1.9 F. Hoffmann-La Roche Ltd (Ventana Medical Systems Inc.)
6.1.10 Visiopharm A/S
6.1.11 Sectra AG
6.1.12 Leica Biosystems
6.1.13 XIFIN, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS